1. Home
  2. PCLA vs CVKD Comparison

PCLA vs CVKD Comparison

Compare PCLA & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCLA
  • CVKD
  • Stock Information
  • Founded
  • PCLA 2008
  • CVKD 2022
  • Country
  • PCLA Japan
  • CVKD United States
  • Employees
  • PCLA N/A
  • CVKD N/A
  • Industry
  • PCLA Building Products
  • CVKD Medicinal Chemicals and Botanical Products
  • Sector
  • PCLA Consumer Discretionary
  • CVKD Health Care
  • Exchange
  • PCLA Nasdaq
  • CVKD Nasdaq
  • Market Cap
  • PCLA 71.3M
  • CVKD 29.5M
  • IPO Year
  • PCLA 2025
  • CVKD 2023
  • Fundamental
  • Price
  • PCLA $3.13
  • CVKD $12.54
  • Analyst Decision
  • PCLA
  • CVKD Strong Buy
  • Analyst Count
  • PCLA 0
  • CVKD 1
  • Target Price
  • PCLA N/A
  • CVKD $32.00
  • AVG Volume (30 Days)
  • PCLA 2.5M
  • CVKD 36.2K
  • Earning Date
  • PCLA 01-01-0001
  • CVKD 08-06-2025
  • Dividend Yield
  • PCLA N/A
  • CVKD N/A
  • EPS Growth
  • PCLA N/A
  • CVKD N/A
  • EPS
  • PCLA N/A
  • CVKD N/A
  • Revenue
  • PCLA $5,475,228.00
  • CVKD N/A
  • Revenue This Year
  • PCLA N/A
  • CVKD N/A
  • Revenue Next Year
  • PCLA N/A
  • CVKD N/A
  • P/E Ratio
  • PCLA N/A
  • CVKD N/A
  • Revenue Growth
  • PCLA 40.19
  • CVKD N/A
  • 52 Week Low
  • PCLA $0.37
  • CVKD $5.70
  • 52 Week High
  • PCLA $9.80
  • CVKD $22.90
  • Technical
  • Relative Strength Index (RSI)
  • PCLA N/A
  • CVKD 49.98
  • Support Level
  • PCLA N/A
  • CVKD $11.00
  • Resistance Level
  • PCLA N/A
  • CVKD $13.56
  • Average True Range (ATR)
  • PCLA 0.00
  • CVKD 1.15
  • MACD
  • PCLA 0.00
  • CVKD 0.25
  • Stochastic Oscillator
  • PCLA 0.00
  • CVKD 80.97

About PCLA PicoCELA Inc. American Depositary Shares

PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Share on Social Networks: